Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Next Gen antibodies seeking to mimic Pelareorep + ICI action
View:
Post by Noteable on Oct 04, 2022 11:11am

Next Gen antibodies seeking to mimic Pelareorep + ICI action

Next-generation multi-specific antibodies, which target multiple antigens or epitopes on the same antigen, seek design to target multiple cells in the tumour microenvironment, rather than a singular molecular pathway, just as ONCY's multifunctional pelareorep is capable of doing. 

The next generation anitbodies aim to influence tumour death through various mechanisms including T cell costimulation, engagement of innate and adaptive immune cells, inhibition of specific mutation-driven signalling pathways, blockade of immune checkpoints, and targeting multiple antigens to increase tumour selectivity, just like ONCY's pelareorep in combination with immune checkpoint inhibitors are capable of achieving.

Furthermore, with the understanding of complex interactions between tumour and immune cells in the TME advances, it is likely we will identify new targets and immune signatures specific to certain cancer types and individuals.

Cancer treatment is inexorably becoming more personalised, and, one day, it may be possible that IO therapy combinations can be routinely tailored for patients based on their specific immune signature.
 
Comment by Noteable on Oct 04, 2022 12:06pm
I would further propose that this development is another reason why ONCY is worth north of US$ 8 Billion, since it is becoming increasingly evident that Big Pharma is seeking multifunctional assets like ONCY's pelareorep that can address the complex interactions between the tumor and the TME - both by engaging the innate / adaptive immune system and modulating the TME in advance of immune ...more  
Comment by Lesalpes29 on Oct 04, 2022 12:17pm
u If we see a buyout at this price, I will ski in Les Alpes next winter! Of course I will be retired too!
Comment by Capitalista on Oct 04, 2022 3:03pm
Lesalpes29, I may see you there!.  I'm going regardless of ONC's fortunes, as YOLO.  Mribel is my chosen venue.   
Comment by Lesalpes29 on Oct 04, 2022 9:41pm
Meribel, nice for you. Been in Chamonix once. Not able to get back there. It was 20 years ago, time goes fast.
Comment by Buckhenry on Oct 04, 2022 8:15pm
I will sell my many shares at a discounted price of 6B to the first person that's responds. please send cash... blue skies
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities